Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006 by Gerber, Nicolas et al.
CLINICAL STUDY – PATIENT STUDY
Outcome of 11 children with ependymoblastoma treated
within the prospective HIT-trials between 1991 and 2006
Nicolas U. Gerber • Katja von Hoff • Andre´ O. von Bueren •
Wiebke Treulieb • Monika Warmuth-Metz • Torsten Pietsch •
Niels Soerensen • Andreas Faldum • Angela Emser • Paul G. Schlegel •
Frank Deinlein • Rolf-Dieter Kortmann • Stefan Rutkowski
Received: 12 May 2010 / Accepted: 6 August 2010 / Published online: 11 February 2011
 Springer Science+Business Media, LLC. 2011
Abstract Ependymoblastoma is a rare malignant brain
tumor of early childhood. Data on clinical behavior and
optimal treatment strategies are scarce. We report on 11
consecutively treated children with centrally confirmed
diagnosis of CNS ependymoblastoma, registered between
February 1994 and October 2006 to the prospective GPOH-
HIT multicenter brain tumor trials, and treated by multi-
modal regimens. Median age at diagnosis was 3.5 years
(range, 1.8–5.6 years), and the median follow-up of survi-
vors was 5.9 years (range, 2.2–12.7 years). Initial stage was
M0 in 9, and M0/1 (no cerebrospinal fluid examination
done) in 2 patients. Gross-total tumor resection was
achieved in 7 patients, incomplete resection in 4 patients.
Further primary therapy included chemotherapy in all
patients, craniospinal radiotherapy in 5 patients and high-
dose chemotherapy in 2 patients. Tumor response to che-
motherapy was observed in 1 of 4 evaluable patients. Tumor
progression occurred in 7 patients after a median time of
5.0 months (range, 2.5–19.2 months). Five-year progres-
sion-free survival was 36.4% (±14.5%), 5-year overall
survival 30.3% (±15.9%). Of 4 survivors, 3 had gross-total
tumor resection, and all were treated by either craniospinal
radiotherapy and/or high-dose chemotherapy with autolo-
gous blood stem cell rescue. Prognosis of children with
ependymoblastoma is poor, but sustained remissions have
been achieved after multimodal treatment. Considerable
diagnostic discrepancies between local and central pathol-
ogists underscore the importance of central review. Further
studies are needed to improve survival of children with this
rare malignant central nervous system tumor.
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Introduction
Ependymoblastoma is a rare malignant tumor of the central
nervous system (CNS) described by Rubinstein in 1970 as
a special type of embryonal CNS neoplasm arising in
young children. So far, information on the incidence is
lacking in the literature. Cytologic features of a primitive,
highly cellular neuroepithelial tumor are associated with
the characteristic presence of numerous ependymoblastic
rosettes [1]. In the current WHO Classification of Tumours
of the Central Nervous System (2007), they are classified
among embryonal tumors as a subgroup of CNS primitive
neuroectodermal tumors (PNET) (WHO grade IV) [2].
They occur mainly in young children; however, single
cases of fetal tumors and one case in an adult have been
described [3, 4]. Location is most often supratentorial, but
infratentorial or spinal sites occur as well [2]. Locations
outside the CNS have been reported, e.g., the cases of a
congenital sacrococcygeal [5] or an ovarian tumor [6].
Ependymoblastomas show an aggressive behavior with
rapid growth and craniospinal dissemination. Prognosis is
generally reported as unfavorable in selected cases [2, 3, 7].
So far, clinical data on ependymoblastoma have mostly been
available as case reports or have been included in analyses
of other PNETs or ependymomas without separate reports
on outcome. Due to the rarity of the disease, little is known
about efficient treatment strategies.
Here, we report on 11 consecutive children with epen-
dymoblastoma treated according to the prospective GPOH
(German Society of Pediatric Oncology and Hematology)
multicenter trials HIT’91, HIT-SKK’92, and HIT 2000
(HIT: German abbreviation for brain tumor).
Patients and methods
Patients
Eleven consecutively treated patients with ependymoblas-
toma diagnosed by central pathology review between Feb-
ruary 1994 and October 2006 were treated at 11 different
institutions within the GPOH multicenter brain tumor trials
HIT’91 [8–10], HIT-SKK’92 [11, 12], and HIT 2000
besides patients with other malignant brain tumor histolo-
gies. There were no patients with centrally confirmed
ependymoblastoma in the studies HIT-SKK’87 [9, 12] and
HIT’88/’89 [10, 12, 13].
Surgery
Maximal safe surgical removal of the primary tumor,
depending on the anatomical location of the tumor and the
condition of the child, was recommended. If intraventric-
ular chemotherapy was part of the treatment protocol, a
subcutaneous reservoir with an intraventricular catheter (an
Ommaya or a Rickham reservoir) was implanted in the
anterior horn of a lateral ventricle after confirmation of
diagnosis. Postoperative therapy started 2–4 weeks after
surgery.
Diagnostic procedures
Eighteen children with a local diagnosis of ependymoblas-
toma were initially registered. In 16 patients, tumor material
was available for central review, the two cases without
available material are not taken into account in this analysis.
On central review, the diagnosis was confirmed in only 7 of
those 16 cases. In the other cases, local diagnoses of epen-
dymoblastoma were anaplastic ependymoma (5 patients),
medulloblastoma (3 patients), and glioblastoma multiforme
(1 patient) at central review. On the other hand, central
review (conducted at the same pathology center for all
patients enrolled into any of the GPOH brain tumor trials,
which comprise the majority of children with any brain
tumor type in Germany, Austria, and part of Switzerland)
identified 4 novel cases of ependymoblastomas, which had
originally been diagnosed as supratentorial CNS PNET
(2 patients), medulloblastoma and glioblastoma multiforme
(1 case each) by the local pathologist. Here, we report on all
11 patients with centrally confirmed ependymoblastoma.
According to the WHO classification, criteria for the
diagnosis of ependymoblastoma was the histological find-
ing of a primitive neuroepithelial tumor of high cellularity
and the presence of multilayered rosettes composed of
sheets of proliferative undifferentiated cells around a round
central lumen. The tumors were characterized by immu-
nohistochemical reactions with antibodies against GFAP,
vimentin, MAP-2, synaptophysin, neurofilaments, INI-1,
epithelial membrane antigen, cytokeratin, and Ki-67.
Staging included pre- and postoperative cranial mag-
netic resonance imaging (MRI) or computed tomography
(CT), spinal MRI, and evaluation of cerebrospinal fluid
(CSF) cytology as described [8–12]. Postoperative imaging
no later than 48(-72) h after surgery was recommended, as
was lumbar CSF-sampling 14 days postoperatively in cases
of previous positive cytology and if no negative lumbar
CSF has been sampled before. The presence of microscopic
CSF and macroscopic solid or laminar metastases was
evaluated according to the tumor staging system of Chang
and colleagues [14], with stage M0 denoting absence of
metastases, stage M1 disseminated tumor cells in the CSF,
stage M2 intracranial macroscopic metastases, and stage
M3 spinal macroscopic metastases. Patients without mac-
roscopic metastases who did not get CSF-cytology sam-
pling are referred to as M0/1.
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Resection was defined as gross-total if no residual tumor
was detected on postoperative imaging. Complete response
was defined as the total disappearance of residual tumor
during chemotherapy or at the end of treatment. Partial
response was defined as a decrease of more than 50% in the
tumor volume, improvement as a decrease of at least 25%,
but less than 50%, stable disease as a decrease of less than
or an increase of 25% at the most, and progressive disease
as an increase of more than 25%.
Besides histopathology, central review was recom-
mended for radiology, CSF cytology, and documentation of
radiotherapy and chemotherapy. During and after treat-
ment, regular clinical and radiologic follow-up were rec-
ommended according to the respective protocols.
Treatment protocols
(1) HIT’91: The study was open for patients between 3 and
18 years of age with malignant brain tumors newly
diagnosed between August 1991 and December 1997,
with a prolongation on an interim base until December
2000. Patients were randomly assigned to receive
either immediate radiotherapy [35.2 Gray (Gy) on
craniospinal axis/20.0 Gy boost on tumor bed] followed
by ‘maintenance’ chemotherapy [1-(2-chloroethyl)-3-
cyclohexyl-1-nitrosourea (CCNU), vincristine, and
cisplatin], or immediate preradiation ‘sandwich’ che-
motherapy (ifosfamide, etoposide, methotrexate, cis-
platin, and cytarabine) followed by radiotherapy, which
was followed by maintenance chemotherapy in cases of
residual tumor [8–10].
(2) HIT-SKK’92: Patients under 3 years of age with
malignant brain tumors diagnosed between October
1992 and December 1997 received ‘SKK’ chemother-
apy (cyclophosphamide, vincristine, methotrexate,
carboplatin, and etoposide) plus intraventricular meth-
otrexate. In cases of complete remission, no further
therapy was given. Otherwise, children aged at least
18 months received radiotherapy (35.2 Gy craniospi-
nal/20.0 Gy boost); children younger than 18 months
received experimental chemotherapy [12, 15].
(3) HIT 2000: In this prospective multicenter trial, children
with ependymoblastoma were stratified together with
supratentorial CNS-PNET/pineoblastoma according to
age and M-stage.
3.1 HIT 2000 below 4 years, non-metastatic disease:
3.1.1. Patients diagnosed from January 2001 to
December 2004 (before amendment)
initially received ‘SKK’ chemotherapy.
Patients with complete remission received
additional cycles of ‘SKK’ chemother-
apy without methotrexate followed by
radiotherapy (24.0 Gy craniospinal/30.6
Gy boost to tumor bed plus 5.4 Gy on any
residual tumor). The other patients
directly received radiotherapy with con-
comitant vincristine, followed by mainte-
nance chemotherapy.
3.1.2. Patients diagnosed from January 2005
onwards were treated with carbo-
platin, etoposide, and intraventricular
methotrexate. In cases of partial or com-
plete response, 2 high-dose chemotherapy
(HDCT) courses were given (carboplatin/
etoposide and thiotepa/cyclophospha-
mide, plus intraventricular methotrexate),
each followed by autologous blood stem
cell transplantation. Subsequent radio-
therapy was given to all patients who
were not in complete remission after the
HDCT, and optional for patients who
were not in complete remission before but
in complete remission after HDCT.
Radiotherapy was omitted by patients
already in complete remission before
HDCT. Patients who did not fulfill the
HDCT criteria directly received radio-
therapy after the induction chemotherapy,
followed by maintenance chemotherapy.
3.2 HIT 2000 older than 4 years, non-metastatic
disease: Patients enrolled from January 2005
onwards were treated with ‘SKK’ chemotherapy,
followed by hyperfractionated radiotherapy
(36.0 Gy craniospinal/30 Gy boost on tumor
bed plus additional boost on any residual tumor)
plus concomitant weekly vincristine, followed by
maintenance chemotherapy.
Informed consent was obtained from all patients
and/or their legal representatives. The study
protocols were approved by the Ethics Commit-
tee of the University of Wuerzburg and per-
formed in accordance with the ethical standards
laid down in the Declaration of Helsinki and its
amendments.
Statistical analyses
Survival functions were estimated by the method of Kaplan
and Meier. Overall survival (OS) was defined as time from
primary surgery to death by any cause or last evaluation,
whichever came first, and progression-free survival (PFS)
as the time from primary surgery to first documented
progressive disease, to death by any cause, or to last
evaluation, whichever came first. Due to the small number
J Neurooncol (2011) 102:459–469 461
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of patients, no univariable or multivariable statistical
analyses were done. Analysis was performed with SPSS
software, version 16.0.
Results
Patient numbers and characteristics
A total of 11 consecutively treated patients with ependy-
moblastoma as diagnosed by central pathology review
between February 1994 and October 2006 were identified
among the patients enrolled into the appropriate GPOH
pediatric brain tumor studies: HIT’91, 2 patients; HIT-
SKK’92, 1 patient; and HIT 2000, 8 patients. Details are
summarized in Table 1. There were no such patients treated
within the studies HIT-SKK’87 and HIT’88/’89. Median age
at diagnosis was 3.5 years (range, 1.8–5.6 years). All
patients were male. Tumor location was supratentorial in 8
patients (frontal, 1; fronto-temporal, 1; fronto-parietal, 2;
parietal, 3; and 3rd ventricle, 1 patient) and infratentorial in 3
patients (cerebellopontine angle, pons/cerebellar peduncle,
and 4th ventricle, 1 patient each) (Figs. 1 and 2). None of the
patients had macroscopic central nervous system metastases
or systemic metastases outside the central nervous system at
diagnosis. Initial cerebrospinal fluid (CSF) samples were
normal in 9 patients (M0 stage), and initial CSF examination
was not done in 2 patients (M0/1 stage). Median follow-up
time of surviving patients since diagnosis was 5.9 years
(range, 2.2–12.7 years).
Histopathology
Histopathology showed the typical features of ependy-
moblastomas with highly cellular appearance, promi-
nent multilayered (ependymoblastic) rosettes with central
lumina. The tumors lacked ependymal features such as
dominant perivascular rosettes or ependymal rosettes.
Rhabdoid components or features of medulloepitheliomas
such as a dominant trabecular pattern was absent. Most
tumor cells expressed MAP2 and vimentin; a predominant
GFAP positivity was not found. A dot- or ring-like EMA
reactivity characteristic for ependymomas was not found.
Cytokeratin expression was not found in a significant
fraction of tumor cells. The nuclear INI-1 was retained.
With antibodies against synaptophysin and neurofila-
mants, an abundant portion of neuropil was not demon-
strated as suggested to be typical for ETANTR, a PNET
variant recently described [16, 17]. KI-67 labeling dem-
onstrated a high proliferative activity of the tumor cells,
especially in the cells forming multilayered ependymob-
lastic rosettes.
Treatment and outcome
Tumor resection as assessed by early postoperative imag-
ing was gross-total in 7 (all supratentorial), and incomplete
in 4 patients (infratentorial, 3; supratentorial, 1 patient).
Postoperative treatment according to the respective therapy
protocols are described in Table 1. Postoperative first-line
treatment consisted of (conventional dose) chemotherapy
followed by craniospinal radiotherapy in 3 patients (nos. 1,
9, and 10; 2 of them with additional maintenance chemo-
therapy). Two of these patients remained in continuous
complete remission during the whole therapy, one of those
showing a tumor relapse a few months later. The third
patient suffered a combined local and distant relapse whilst
under maintenance chemotherapy after initially having
shown a complete response to induction chemotherapy. Of
the 2 patients (nos. 2 and 11) who were initially treated
with craniospinal radiotherapy followed by chemotherapy,
1 remained in continuous complete remission, the other had
additional high-dose chemotherapy followed by autologous
stem cell transplantation with clinically stable disease.
Thus, 3 of the 5 patients receiving craniospinal radiother-
apy as part of their primary treatment remained free of
tumor progression. Two patients with gross-total resection
initially remained in continuous complete remission under
postoperative conventional dose chemotherapy followed by
high-dose chemotherapy with autologous stem cell trans-
plantation (nos. 6 and 7), one of these patients suffered a
relapse a few months later. Four patients (nos. 3, 4, 5, and
8) showed progressive disease already under primary
postoperative chemotherapy. Protocol deviations can be
seen from Table 1.
In summary, 7 patients had a tumor progression with a
median time to progression of 5.0 months after diagnosis
(range, 2.5–19.2 months), all died of disease at a median of
1.1 years after primary diagnosis (range, 0.3–3.1 years).
Five-year progression-free survival probability was 36.4%
(±14.5%) (Fig. 3). Five-year overall survival probability
was 30.3% (±15.9%). The pattern of relapse was combined
(local and distant) in 5 cases with a spinal distant compo-
nent in 3 and a supratentorial component in 2 cases; local
with secondary spinal spread in 1 patient; and distant
(spinal) only in 1 patient.
After tumor progression, salvage treatment consisted in
partial resection followed by radiotherapy and chemotherapy
in 1 patient, craniospinal radiotherapy alone in 1 patient,
chemotherapy followed by craniospinal radiotherapy in 2
patients, chemotherapy, immunotherapy and hyperthermia
therapy in 1 patient, chemotherapy only in 1 patient, and no
salvage treatment was given in 1 case. None of the tumors
responded to salvage treatment, and, accordingly, all 7
patients eventually died of tumor progression.
462 J Neurooncol (2011) 102:459–469
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Tumor response to adjuvant treatment could be assessed
in those 4 patients with incomplete tumor resection. One
patient initially showed a complete response to 2 cycles of
‘SKK’ chemotherapy, which was maintained during radio-
therapy, but he relapsed during maintenance chemotherapy.
One patient had continuous stable disease under craniospi-
nal radiotherapy, 7 cycles of ‘SKK’ chemotherapy, and
high-dose chemotherapy with temozolomide until last fol-
low-up 2.3 years after diagnosis. Two patients showed early
progression under ‘SKK’ chemotherapy.
Four patients were alive at last follow-up, 3 of them in
continuous complete remission (2.2, 9.4, and 12.7 years
after diagnosis) and 1 with stable disease (2.3 years after
diagnosis). All the 3 patients with complete remission at
last follow-up initially had gross-total tumor resection
followed by intensive adjuvant treatment including either
craniospinal radiotherapy (2 patients) or 2 successive high-
dose chemotherapy courses with autologous blood stem
cell transplantation (1 patient). One survivor, who had been
treated with craniospinal radiotherapy, was diagnosed with
papillary thyroid carcinoma 9.4 years after diagnosis of the
ependymoblastoma.
Discussion
Here, we report on 11 consecutively treated children with
ependymoblastoma diagnosed between 1994 and 2006 and
treated within the prospective multicenter GPOH HIT-
studies for malignant brain tumors of childhood. To our
knowledge, this is the largest original series on this rare
tumor entity. Our study confirms the aggressiveness of this
tumor and unfavorable survival rates described in individ-
ual cases by others [2, 3, 7]. Despite intensive multimodal
treatment, 7 patients died of tumor progression. Tumor
response to treatment was assessable in all 4 patients with
less than gross-total tumor resection. A complete response
to chemotherapy was observed in 1 patient; however, this
patient relapsed after further radiotherapy and chemother-
apy. Two patients had an early progression during chemo-
therapy, while the fourth patient had stable disease under
radiotherapy and chemotherapy including high-dose che-
motherapy. Progressions occurred early at a median time of
Fig. 1 a Preoperative axial
T2-weighted MRI of patient
no. 8 showing low signal
intensity characteristic for a
highly cellular tumor in the
solid lateral parts of the left
frontal tumor. The central high
signal areas represent necrotic
parts. b The medulla oblongata
is displaced to the right by a
probably highly cellular tumor
within the left cerebellopontine
cistern showing an
inhomogeneous reduced signal
on this preoperative axial
T2-weighted MRI of patient
no. 11. The basilar artery is
partially encased by tumor
Fig. 2 Histology of case no. 10. Hematoxylin and eosin staining
illustrates primitive neuroepithelial tumor composed of immature
progenitor cells forming numerous multilayered proliferative rosettes
with central lumina (ependymoblastomatous rosettes)
J Neurooncol (2011) 102:459–469 465
123
5 months after diagnosis, most patients still being under
treatment. Despite preceding systemic chemotherapy in all
and craniospinal radiotherapy in 2 patients, most of the
progressions had a distant component within the CNS.
Salvage treatment, which was multimodal in most patients,
including chemotherapy in 5 cases, and craniospinal irra-
diation in 4 cases, did not lead to tumor responses, and
finally all patients with tumor progression died of disease.
Four patients survived at a median time of 6 years after
diagnosis, of which 3 patients remain in complete remis-
sion. They all received intensive multimodal treatment
consisting of surgery and chemotherapy in all cases,
radiotherapy including 35–36 Gy to the craniospinal axis
plus a local boost in 3 patients, and double HDCT with
autologous blood stem cell transplantations in 1 patient. All
but 1 surviving patients had a primarily gross-total resec-
tion, and only those 3 patients were in complete remission
at last follow-up. Three out of 5 patients who received
radiotherapy as part of their primary treatment are still
alive, 2 in complete remission 9.4 and 12.7 years after
diagnosis. In contrast, 5 patients out of 6 died after che-
motherapy alone. One patient with previous radiotherapy
developed a papillary thyroid carcinoma 9 years after
diagnosis.
Comparison of our data with other data is only possible
to a limited degree, as ependymoblastomas are very rare
tumors, having been reported either as single case reports,
frequently with no or only scant data on treatment and
follow-up, or as part of larger reports on CNS PNET, mostly
including a maximum of 1 to 3 children with ependymo-
blastoma, the outcome usually not being separately
accounted for [7, 18–24]. The largest series dates from 1985
assembling 12 cases, which had been partially previously
published by other authors in the pre-MRI era between 1970
and 1980 [3]. Age ranges were comparable to our study with
predominantly young children between fetal age and
5 years old; however, with the exception of one 16-year-old
and one 32-year-old patient. Seven patients were male, 5
were female. Localization was supratentorial in 8, infra-
tentorial in 3, and both combined in 1 case. Only 7 patients
had surgery as part of the treatment regimen, 5 had radio-
therapy, and 3 had chemotherapy. Median overall survival
was 12 months, with longer survival of those with radio-
therapy or chemotherapy. All patients died of progression
except for 1 (with a short follow-up time). Interestingly, 1
patient had extracranial tumor growth at the craniotomy
site and pulmonary metastases at follow-up. Our results
compare favorably to this series, probably due to the more
aggressive multimodal treatment regimens applied to the
patients in our series. Histology of 5 patients with
ependymoblastomas was described by Cruz-Sanchez in
1988 [25]. Apart from age at diagnosis (0.7–14 years), sex
(3, male; 2, female), and tumor localization (4, supraten-
torial; 1 infratentorial; all related to the ventricles), no
clinical data are given. As in our series, localization of
ependymoblastomas was more often supratentorial than
infratentorial [3, 7, 25, 26]; however, single cases of
transtentorial extension, spinal localization, and primary
leptomeningeal spread have been described [3, 27, 28].
Primary extra-CNS localization has been observed,
including ovary and sacrococcygeal soft tissue [5, 29, 30].
Metastatic spread occurs mostly in the CNS; however,
single cases of pulmonary and lymph node metastases have
also been found [3, 26, 31, 32]. In many case reports, no
information is given on treatment and follow-up. In most of
those cases where such information is available, the patients
died within several months to a few years. Due to the small
total of patients, heterogeneous patient and treatment
characteristics as well as availability of information, no
prognostic factors can be detected.
The diagnoses of all patients reported in this study have
been made by central reference pathology according to the
Fig. 3 Progression-free (a) and overall (b) survival rates of 11
patients with ependymoblastomas
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current WHO classification of brain tumors [2]. There were
considerable discrepancies between diagnoses from local
and reference pathologists. In 9 of 16 patients with local
diagnosis of ependymoblastoma and tumor material avail-
able for central review, the diagnoses of anaplastic epen-
dymoma, medulloblastoma, and glioblastoma were made
by central review. Thus, only 7 out of 16 (44%) of local
diagnoses of ependymoblastoma could be centrally con-
firmed. On the other hand, the central pathologist identified
4 ependymoblastoma patients with former local diagnoses
of CNS PNET, medulloblastoma, and glioblastoma multi-
forme. Similar diagnostic challenges have been observed by
others: in a trial enrolling 32 patients with centrally diag-
nosed ependymoma, 9 of them were initially diagnosed as
ependymoblastoma by the local pathologists [33], and other
divergent diagnoses included medulloepithelioma [18].
These discrepancies strongly support the importance of
central pathology review, not only in the context of clinical
trials. The importance of a precise histological diagnosis is
additionally underscored by the fact that there are no known
clinical or radiological features distinguishing ependy-
moblastomas from other tumor types. It is essential that
publications about ependymoblastoma must be studied
carefully, as some case reports might in fact represent other
tumor entities due to incorrect diagnosis. Furthermore,
ependymoblastomas have wrongly been defined—not in
accordance with the current WHO Classification of
Tumours of the Central Nervous System—as high-grade
ependymomas, as done in a publication describing the
largest series of patients with ‘‘ependymoblastoma’’ [34].
The tumors described here fulfill the histological criteria
for the diagnosis of ependymoblastoma as defined by the
current WHO Classification of Brain Tumors [2]. Recently, a
primitive tumor characterized as embryonal tumors with
abundant neuropil and true rosettes (ETANTR) has been
described [17]. Some authors believe that they have identified
a novel histologic entity with combined features of ependy-
moblastoma and neuroblastoma, heavily cellular regions and
fibrillar neuropil-like areas containing mitotically active and
multilayered ependymoblastomatous rosettes (here called
‘‘true’’ rosettes), and with poor clinical outcome [16, 17, 35,
36]. However, this phenotype largely overlaps with original
histological descriptions of such tumors by Rubinstein in
1970 [1] and may represent the identical tumor entity.
Therefore, the ETANTR has not been accepted as a novel
entity by the current WHO Classification of Tumours of the
Central Nervous System [2, 16, 17, 35, 36].
Our study has several strengths: to the best of our
knowledge, it is the largest series of recently published
patients, histologies were centrally reviewed, all patients
diagnosed with ependymoblastoma within the indicated
time period are reported on, treatments were given
according to contemporary protocols for PNET, and
follow-up time of survivors is relatively long. However, we
are also aware of limitations: the number of patients is
small, hence possible prognostic factors cannot be analyzed
statistically. Due to the time period covered by patients
from our series, patients were not treated homogeneously.
Nevertheless, we believe that our study contributes to the
understanding of this rare disease, and it demonstrates that
the disease may be cured in some of the patients. Local
tumor control seems to be of importance in this disease, as
most survivors had gross-total tumor resection. Further-
more, all survivors had aggressive postoperative treatment
containing radiotherapy and/or high-dose chemotherapy
with autologous blood stem cell rescue. Radiotherapy as part
of primary treatment seemed to have a positive effect on
survival; however, it did not confer a sustained benefit as
part of salvage strategies in patients with tumor progression
during initial postoperative chemotherapy. A future
approach using upfront radiation therapy seems to be a prom-
ising strategy to improve outcome. The selection of target
volumes and necessary dose prescriptions are still open
questions. For instance, restrictions of the irradiation field to
the tumor bed only, which have been successfully estab-
lished in treatment concepts for children with intracranial
ependymoma with clinically relevant benefits in long-term
toxicities and neuropsychological deficits, might be an
option worth investigating, especially in very young chil-
dren [37, 38]. Also, the role of chemotherapy has to be
further clarified: whereas one patient survived after high-
dose chemotherapy without radiotherapy and response to
chemotherapy was observed in another patient, 4 early
relapses were observed during postoperative chemotherapy
in our series. It thus seems that, at least in patients with
incomplete tumor resection, any pre-irradiation induction
chemotherapy should be kept short, as the risk of early
relapse during chemotherapy may be considerable.
In summary, our series show that some patients with
ependymoblastomas may be cured by surgical treatment
followed by either a combination of radiotherapy and che-
motherapy or by chemotherapy including high-dose therapy
without irradiation. However, it remains unclear which of
these approaches is the most promising, and the optimal
sequence of the different therapy modalities has yet to be
defined. Clearly, further research on clinical behavior, tumor
biology and potential prognostic factors is warranted, and
effective risk-adapted treatment recommendations, opti-
mizing the balance between treatment intensity and adverse
treatment effects, need to be improved.
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